Sasanlimab

萨善利单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameSasanlimab
Drug Alias NameRN-888PF-06801591PF-6801591
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSkin MelanomaGastroesophageal Junction NeoplasmsSolid tumours +[38] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[23] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMaastricht University Medical CenterPfizer IncPfizer Manufacturing Belgium Nv +[5] 
Inactive CompaniesSeagen Inc
Active IndicationsSolid tumoursFructose IntoleranceUrinary Bladder Neoplasms +[7] 
Inactive IndicationsSkin MelanomaGastroesophageal Junction NeoplasmsKidney Diseases +[31] 

Other Information

ATC CodeN/A
Related LinksN/A